DongKook Life Science

At a glance

DongKook Life Science filed 20 disclosures in the last 12 months, including 2 insider and 1 5% holder. The most recent key filing was on Jul 2.

Revenue for 2025 was ₩130B, down 1.1% on 2024. Operating margin was 10% against 9% a year earlier. Debt was 66% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩57.3B and operating profit of ₩3.5B.

The 2025 annual report lists 203 employees with an average tenure of 4.3 years and average pay of ₩64.5M, #782 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩164M each on average. It paid no cash dividend for 2025. 동국제약(주) and related parties held 62.02% at year end.

From the 2025 annual report

Staff: 203 (151 men, 52 women), of whom 6 on fixed-term contracts. Total pay for the year: ₩13.1B. Directors and auditors: 6, paid ₩983.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

동국제약(주) holds 39.50%; with 15 related parties the group holds 62.02% of common shares at year end (from 71.19% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary